GSK stock: At 17.97 percent below its 52-week high, GSK stock sits

Published on 10/20/2026 at 15:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EMBOLD recorded a 61.00 percent response rate. GSK stock costs EUR 22.36 on October 20, 2026, up 1.64 percent versus Xetra close.

Trial data and market position

The EMBOLD study recorded a 61.00 percent response rate at 8mg/kg on October 19, 2026.
GSK had a market capitalization of USD 100.6 billion on October 20, 2026.
GSK stock costs EUR 22.36 at Lang & Schwarz on October 20, 2026 at 3:35 p.m. CEST, 1.64 percent above the Xetra close of October 19, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK stock stood 17.97 percent below its 52-week high of GBp 2,282.00 on October 20, 2026. The EMBOLD study recorded a 61.00 percent response rate at 8mg/kg, according to Yahoo Finance on October 19, 2026. GSK was trading at EUR 22.36 at Lang & Schwarz on October 20, 2026 at 3:35 p.m. CEST, up 1.64 percent versus the Xetra close of October 19, 2026 at EUR 22.00.

Trial response reaches 61.00 percent

The EMBOLD study involved extensive-stage small-cell lung cancer patients receiving the experimental antibody-drug conjugate risvutatug rezetecan. The 8mg/kg group recorded 11 responses among 18 patients, while the 6mg/kg group recorded 7 responses among 22 patients, according to Yahoo Finance.

The same report said the 8mg/kg group had treatment-related adverse events in 42.00 percent of patients. Progression-free survival had not yet been reported, leaving a further clinical measure outstanding.

Stock stays below its annual high

GSK's LSE quote was GBp 1,872.00 on October 20, 2026, against a 52-week low of GBp 1,592.00 and a 52-week high of GBp 2,282.00. The high-to-price distance was 17.97 percent, while the price stood 17.59 percent above the low. The Lang & Schwarz euro quote was 1.64 percent above the Xetra close.

Results date and valuation

GSK is scheduled to report third-quarter 2026 results on October 28, 2026, before the market opens, according to MarketBeat. Its consensus estimate is USD 1.33 earnings per share on USD 11.74 billion in revenue, compared with USD 1.48 and USD 11.35 billion in the year-earlier quarter.

GSK had a market capitalization of USD 100.6 billion and a trailing P/E ratio of 15.73 on October 20, 2026. The dividend yield was 4.00 percent, giving the upcoming results a clear role in testing the current valuation.

GSK price and investor perspective

The stock's 1.64 percent premium to the October 19, 2026 Xetra close places the euro quote above the prior German reference level, while the LSE price remains below its 52-week high. The next results date supplies the nearest scheduled company event.

GSK was trading at EUR 22.36 at Lang & Schwarz on October 20, 2026 at 3:35 p.m. CEST, 1.64 percent above the Xetra close of October 19, 2026 at EUR 22.00. The further course of trading is shown by the continuously updated real-time quote of GSK stock.